RYTM SEC-Einreichungen - Rhythm Pharmaceuticals, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

LEI	529900JPNWXQ8DPLA551
CIK	1649904

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rhythm Pharmaceuticals, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 29, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini
May 5, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 RHYTHM PHARMACEUTICALS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Other Deferred Compensation Obligations Other 1,500,000 $ 1.00 $ 1,500,000.00 0.0001381 $ 207.15 Total Offering
May 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 RHYTHM PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissio
May 5, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHY
May 5, 2026	EX-99.1	Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update -- IMCIVREE® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following F Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - IMCIVREE® (setmelanotide) launched in the U.
May 5, 2026	S-8	As filed with the Securities and Exchange Commission on May 5, 2026 As filed with the Securities and Exchange Commission on May 5, 2026 Registration No.
May 5, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defini
May 5, 2026	EX-10.1	Rhythm Pharmaceuticals, Inc. Deferred Compensation Plan (Directors) Effective Date May 1, 2026 EXHIBIT 10.1 Rhythm Pharmaceuticals, Inc. Deferred Compensation Plan (Directors) Effective Date May 1, 2026 Rhythm Pharmaceuticals, Inc. Deferred Compensation Plan (Directors) Table of Contents Article I Establishment and Purpose 1 Article II Definitions 1 Article III Eligibility and Participation 5 Article IV Deferrals 5 Article V Payments from Accounts 8 Article VI Valuation of Account Balances;
April 29, 2026	ARS	ARS 2025 ANNUAL REPORT About Rhythm Pharmaceuticals Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients living with rare neuroendocrine diseases.
April 29, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a
April 3, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 RHYTHM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
April 3, 2026	EX-99.1	Rhythm Pharmaceuticals Announces Changes to Board of Directors -- Kim Popovits appointed as new Director; Ed Mathers to depart -- Rhythm Pharmaceuticals Announces Changes to Board of Directors - Kim Popovits appointed as new Director; Ed Mathers to depart - BOSTON, April 3, 2026 – Rhythm Pharmaceuticals, Inc.
March 26, 2026	EX-99.1	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment -- European Commission deci Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment - European Commission decision anticipated in second quarter of 2026 - BOSTON, March 26, 2026– Rhythm Pharmaceuticals, Inc.
March 26, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 RHYTHM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
March 20, 2026	EX-99.1	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity -- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by acce EXHIBIT 99.1 Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – - Indicated to reduce excess body weight and maintain red
March 20, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 RHYTHM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
March 20, 2026	EX-99.2	© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® March 19, 2026 Rhythm Pharmaceuticals IMCIVREE (Setmelanotide) FDA Approval in Acquired Hypothalamic Obesity EXHIBIT 99.2 ® 2 On Today’s Call • David Connolly, Vice President of Investor Relation ex992ahoapprovaldeckfina © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® March 19, 2026 Rhythm Pharmaceuticals IMCIVREE (Setmelanotide) FDA Approval in Acquired Hypothalamic Obesity EXHIBIT 99.2 ® 2 On Today’s Call • David Connolly, Vice President of Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Jennifer Lee, Executive Vic
March 16, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 RHYTHM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
March 16, 2026	EX-99.1	Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial -- Four substudies did not meet pre-specified primary endpoints -- -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with EXHIBIT 99.1 Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial - Four substudies did not meet pre-specified primary endpoints - - Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous variant of the POMC/PCSK1 and SRC1 (NCOA1) genes at 52 weeks – - Conference call planned for 4:30 p.m. ET toda
March 16, 2026	EX-99.2	© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Phase 3 EMANATE Trial Topline Results March 16, 2026 EXHIBIT 99.2 ® 2 On Today’s Call • David Connolly, Executive Director of Investor Relations and Corporate Communication ex992rytm20260313emanate © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Phase 3 EMANATE Trial Topline Results March 16, 2026 EXHIBIT 99.2 ® 2 On Today’s Call • David Connolly, Executive Director of Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Alastair Garfield, Chief Scientific Officer • Hunter Smi
March 2, 2026	EX-99.1	Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity -- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks Exhibit 99.1 Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity - -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity - - March 20, 2026 PDUFA goal date for sN
March 2, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 RHYTHM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
February 26, 2026	EX-99.1	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update -- Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million -- -- March 20, 2026 PDUFA goal date for Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update - Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.
February 26, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 RHYTHM PHARMACEUTICALS, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwar
February 26, 2026	EX-1.2	RHYTHM PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENT Exhibit 1.2 RHYTHM PHARMACEUTICALS, INC. $200,000,000 COMMON STOCK SALES AGREEMENT February 26, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1.             Issuance and Sale of Share
February 26, 2026	S-3ASR	As filed with the Securities and Exchange Commission on February 26, 2026 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on February 26, 2026 Registration No.
February 26, 2026	EX-10.17	[The remainder of this page is intentionally left blank.] May 20, 2024 Alastair Garfield via email [REDACTED] Dear Alastair, Congratulations on your offer of employment with Rhythm Pharmaceuticals, Inc.
February 26, 2026	EX-21.1	Subsidiaries of Rhythm Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Rhythm Pharmaceuticals, Inc. Entity Jurisdiction of Organization or Incorporation Rhythm Securities Corp. Massachusetts Rhythm Pharmaceuticals Canada Inc. Canada Rhythm Pharmaceuticals France SAS France Rhythm Pharmaceuticals Germany GmbH Germany Rhythm Pharmaceuticals Italy S.r.l. Italy Rhythm Pharma K.K. Japan Rhythm Pharmaceuticals Spain, SL Spain Rhythm Pharmaceuti
February 26, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 RHYTHM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
February 26, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 RHYTHM PHARMACEUTICALS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share 457(a) 2,688,212 $ 97.35 $ 261,697,438.20 0.0001381 $ 36,140.42 T
February 26, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYTHM P
February 26, 2026	S-8	As filed with the Securities and Exchange Commission on February 26, 2026 As filed with the Securities and Exchange Commission on February 26, 2026 Registration No.
February 26, 2026	EX-4.3	RHYTHM PHARMACEUTICALS, INC.   Exhibit 4.3     RHYTHM PHARMACEUTICALS, INC.       INDENTURE   Dated as of , 20       []   Trustee           TABLE OF CONTENTS   Page   ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5       ARTICLE II. THE SECURITIES 5 Section 2
January 16, 2026	S-8	As filed with the Securities and Exchange Commission on January 16, 2026 As filed with the Securities and Exchange Commission on January 16, 2026 Registration No.
January 16, 2026	EX-99.1	Rhythm Pharmaceuticals, Inc. Deferred Compensation Plan (Employees) Effective Date January 15, 2026 Exhibit 99.1 Rhythm Pharmaceuticals, Inc. Deferred Compensation Plan (Employees) Effective Date January 15, 2026 Rhythm Pharmaceuticals, Inc. Deferred Compensation Plan (Employees) Table of Contents Article I Establishment and Purpose 1 Article II Definitions 1 Article III Eligibility and Participation 6 Article IV Deferrals 7 Article V Company Contributions 10 Article VI Payments from Accounts 12
January 16, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 RHYTHM PHARMACEUTICALS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Other Deferred Compensation Obligations Other 25,000,000 $ 1.00 $ 25,000,000.00 0.0001381 $ 3,452.50 Total Offe
January 9, 2026	EX-99.1	EXHIBIT 99.1 Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones -- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approxim exhibit991rytmq42025prel EXHIBIT 99.1 Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 - - FY 2025 preliminary net product revenue of
January 9, 2026	8-K	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2026 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commi
January 9, 2026	EX-99.2	© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Corporate Presentation January 2026 EXHIBIT 99.2 ® 2 This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the P exhibit992rytmjanuary20 © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® Rhythm Pharmaceuticals Corporate Presentation January 2026 EXHIBIT 99.2 ® 2 This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters o
December 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 RHYTHM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
December 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 RHYTHM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
December 11, 2025	EX-99.1	Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome -- BMI and hyperphagia reductions have been observed in patients with PWS treate EXHIBIT 99.1 Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome - BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy - - Promising results supportive of
December 11, 2025	EX-99.2	2 ® This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of Exhibit 99.2 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. December 11, 2025 Rhythm Pharmaceuticals Positive Preliminary Results from Phase 2 Trial Evaluating Setmelanotide in Patients with Prader-Willi Syndrome 2 ® This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All sta
November 7, 2025	EX-99.1	Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity -- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- Exhibit 99.1 Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity - FDA sets updated PDUFA goal date of March 20, 2026 – - Company to hold conference today at 8:00 a.m. - BOSTON, November 7, 2025 – Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on trans
November 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 RHYTHM PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
November 7, 2025	EX-99.2	® 2 On Today’s Call • David Connolly, VP, Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Alicia Fiscus, SVP, Head of Regulatory • Hunter Smith, Chief Financial Officer ® 4 Timeline o Exhibit 99.2 © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® November 7, 2025 Rhythm Pharmaceuticals ® 2 On Today’s Call • David Connolly, VP, Investor Relations and Corporate Communications • David Meeker, MD, Chair, President and Chief Executive Officer • Alicia Fiscus, SVP, Head of Regulatory • Hunter Smith, Chief Financial Officer ® 3 This presentation and the accompanying oral presenta
November 4, 2025	EX-99.1	Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update -- Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for Exhibit 99.1 Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update - Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million - - December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity - - Company is on track to report preliminary results from setmelanotide Phase 2 trial in Pr
November 4, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223
November 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 RHYTHM PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
September 2, 2025	144	144 144 0001909855 XXXXXXXX LIVE 0001649904 RHYTHM PHARMACEUTICALS INC 001-38223 222 Berkeley Street, 12th Floor BOSTON MA 02116 8572644280 JOSEPH SHULMAN Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 16781 1730960.
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 RHYTHM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
August 5, 2025	EX-99.1	Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update -- Second quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $48.5 million -- -- U.S. and EU regulatory submissions for setmelano Exhibit 99.1 Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update - Second quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $48.5 million - - U.S. and EU regulatory submissions for setmelanotide in acquired hypothalamic obesity on track to be completed in the third quarter of 2025 - - Bivamelagon Phase 2 trial met primary endpoi
August 5, 2025	EX-10.1	Non-Employee Director Compensation Program EXHIBIT 10.1 Rhythm Pharmaceuticals, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be ma
August 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYT
July 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 RHYTHM PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissi
July 11, 2025	EX-1.1	Underwriting Agreement, dated July 9, 2025, between Rhythm Pharmaceuticals, Inc. and Morgan Stanley & Co. LLC and BofA Securities, Inc., as representatives of the several underwriters named therein. Exhibit 1.1 2,058,824 Shares of Common Stock Rhythm Pharmaceuticals, Inc. Common Stock ($0.001 par value per share) UNDERWRITING AGREEMENT July 9, 2025 July 9, 2025 Morgan Stanley & Co. LLC BofA Securities, Inc. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 Ladies and Gentlemen: Rhythm Pharmaceuticals, Inc., a
July 10, 2025	EX-FILING FEES	Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 RHYTHM PHARMACEUTICALS, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effect
July 10, 2025	424B5	2,058,824 Shares Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270233 PROSPECTUS SUPPLEMENT (To Prospectus dated March 2, 2023) 2,058,824 Shares Common Stock We are offering 2,058,824 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol “RYTM.” On July 9, 2025, the last reported sale price for our common stock on the Nasdaq Global Market wa
July 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 RHYTHM PHARMACEUTICA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissi
July 9, 2025	EX-99.1	Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity -- Bivamelagon achieved BMI reductions in pat Exhibit 99.1 Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks - - Post-hoc analysis sh
July 9, 2025	424B5	Subject to Completion, dated July 9, 2025 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed.
July 9, 2025	EX-99.2	© 2025. Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc. ® July 9, 2025 Rhythm Pharmaceuticals Positive Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Exhibit 99.2 © 2025. Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc. ® July 9, 2025 Rhythm Pharmaceuticals Positive Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Patients with Acquired Hypothalamic Obesity 2 ® This presentation and the accompanying oral presentation contain forward - looking state
June 26, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
June 26, 2025	EX-3.1	Amended and Restated Certificate of Incorporation of Rhythm Pharmaceuticals, Inc. dated October 10, 2017, and the Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Rhythm Pharmaceuticals, Inc. dated June 25, 2025. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RHYTHM PHARMACEUTICALS, INC. Rhythm Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST:The name of the Corporation is “Rhythm Pharmaceuticals, Inc.” The date of filing the original Certificate of Incorporation of the Corporation with the
May 7, 2025	EX-99.1	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update -- First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met EXHIBIT 99.1 Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - First quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $37.7 million - - Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity - - U.S. and EU regulator
May 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHY
May 7, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissio
April 29, 2025	ARS	ARS 2024 ANNUAL REPORTAbout Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients living with rare neuroendocrine diseases.
April 29, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a
April 29, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
April 18, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a
April 7, 2025	EX-99.2	3 ® David Meeker, MD Chair, President and Chief Executive Officer Hunter C. Smith Chief Financial Officer On Today’s Call Susan Phillips, MD Pediatric Endocrinologist at Rady Children's Hospital-San Diego Professor of Pediatrics at UC San Diego Schoo Exhibit 99.2 © 2025. Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc. ® April 7, 2025 Rhythm Pharmaceuticals Positive Topline Results from Phase 3 Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity 2 ® This presentation and the accompanying oral presentation contain forward-looking statements within the
April 7, 2025	EX-99.1	Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity -- Patients with acquired hypothalamic obesity on setmelanotide EX-99.1 2 rytm-20250407xex99d1.htm EX-99.1 Exhibit 99.1 Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity - Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52
April 7, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
March 20, 2025	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
March 20, 2025	EX-99.1	Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. Exhibit 99.1 Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. BOSTON, March 20, 2025 - Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it reacquired the
February 28, 2025	EX-FILING FEES	Filing Fee Table Calculation of Filing Fee Tables S-8 RHYTHM PHARMACEUTICALS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share 457(a) 2,495,626 $ 52.44 $ 130,870,627.44 0.0001531 $ 20,036.29
February 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 RHYTHM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
February 28, 2025	EX-19	Rhythm Global Insider Trading Policy Exhibit 19 Global Insider Trading Policy Effective: 01 Jan 2025 Page: 1 of 8 1 PURPOSE The purpose of this Global Insider Trading Policy (this “Policy”) is to reduce the risk that any employee, executive officer or member of the Board of Directors of Rhythm Pharmaceuticals, Inc.
February 28, 2025	S-8	As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No.
February 28, 2025	10-K	‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 28, 2025	EX-21.1	List of Subsidiaries. Exhibit 21.1 Subsidiaries of Rhythm Pharmaceuticals, Inc. Entity Jurisdiction of Organization or Incorporation Rhythm Pharmaceuticals Limited Ireland Rhythm Securities Corp. Massachusetts Rhythm Pharmaceuticals Netherlands, B.V. The Netherlands Rhythm Pharmaceuticals UK Limited Rhythm Pharmaceuticals France SAS Rhythm Pharmaceuticals Italy S.r.L. Rhythm Pharmaceuticals Canada Inc. United Kingdom F
February 26, 2025	EX-99.1	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update -- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from globa Exhibit 99.1 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million - - On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 - - Completed enrollment in the Phas
February 26, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
February 10, 2025	EX-99	EX-99 EX-99 2 POA13G-2086378520250128.txt EXHIBIT 99 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that THE GOLDMAN SACHS GROUP, INC. (the "Company") does hereby make, constitute and appoint Papa Lette, Akash Keshari, Regina Chan, Andrzej Szyszka, Ameen Soetan, Rahail Patel, Santosh Vinayagamoorthy, Sadhiya Raffique, Matthew Pomfret, Abhishek Vishwanathan, Mariana Audeves, Veronica Mupazviriwo, E
January 10, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
January 10, 2025	EX-99.1	Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones -- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $ Exhibit 99.1 Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones - Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 - - On track to report topline data fro
January 10, 2025	EX-99.2	® 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, s Exhibit 99.2 © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® January 2025 Rhythm Pharmaceuticals ® 2 This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical p
November 14, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm2427451d16ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissi
November 14, 2024	SC 13G	RYTM / Rhythm Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d113430dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76243J105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Ch
November 14, 2024	EX-99.1	AGREEMENT EX-99.1 2 d113430dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: November 14, 2
November 14, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2427451d16sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76243J105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this St
November 12, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / GOLDMAN SACHS GROUP INC Passive Investment SC 13G/A 1 RHYTHM.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* RHYTHM PHARMACEUTICALS, INC. - (Name of Issuer) Common Stock,$0.001 par value per share - (Title of Class of Securities) 76243J105 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check t
November 12, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 rytma7111124.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) COM (Title of Class of Securities) 76243J105 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropri
November 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223
November 5, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
November 5, 2024	EX-99.1	Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update -- Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million -- -- Adult patients with acquired hypothalamic obesity (N=8) ac Exhibit 99.1 Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update - Third quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $33.3 million - - Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program - - Top-line data readout for Pha
September 19, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Co
August 14, 2024	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYT
August 7, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
August 7, 2024	DEFR14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.1) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYT
August 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
August 6, 2024	EX-99.1	Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update -- Second quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $29.1 million -- -- Dosed first patients in supplemental, 12-patient Japanes Exhibit 99.1 Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update - Second quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $29.1 million - - Dosed first patients in supplemental, 12-patient Japanese cohort in global Phase 3 trial evaluating setmelanotide in hypothalamic obesity; On track for topline data from 120-patient, pivotal cohor
August 6, 2024	EX-10.1	Non-Employee Director Compensation Program Exhibit 10.1 Rhythm Pharmaceuticals, Inc. Non-Employee Director Compensation Program Non-employee members of the board of directors (the “Board”) of Rhythm Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or be ma
July 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 RHYTHM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
July 10, 2024	424B7	3,124,995 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(7) Registration No. 333-270233 PROSPECTUS SUPPLEMENT (To Prospectus dated March 2, 2023) 3,124,995 Shares of Common Stock This prospectus supplement relates to the resale or other disposition of up to an aggregate of 3,124,995 shares of our common stock, $0.001 par value per share, that will become issuable upon conversion of the 150,000 shares of
July 10, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Rhythm Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Rhythm Pharmaceuticals, Inc.
June 17, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 17, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
May 7, 2024	EX-3.4	Amended and Restated Certificate of Designations Exhibit 3.4 Rhythm Pharmaceuticals, Inc. Amended and Restated Certificate of Designations Series A Convertible Preferred Stock May 7, 2024 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 14 Section 3. The Convertible Preferred Stock 14 (a) Designation; Par Value 14 (b) Number of Authorized Shares 14 (c) Form, Dating and Denominations 15 (d) Method of Payment; Delay
May 7, 2024	EX-10.5	Third Amendment to Lease, dated May 2, 2024, by and between the Registrant and 500 Boylston & 222 Berkeley Owner (DE) LLC. Exhibit 10.5 TWO TWENTY-TWO BERKELEY STREET Boston, MA Third Amendment to Lease Rhythm Pharmaceuticals, Inc. THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of , 2024 (the “Effective Date”) by and between 500 BOYLSTON & 222 BERKELEY OWNER (DE) LLC, a Delaware limited liability company (“Landlord”), and RHYTHM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). Background A.
May 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHY
May 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 RHYTHM PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissio
May 7, 2024	EX-10.1	Summary of Non-Employee Director Compensation Policy. Exhibit 10.1 Summary of Non-Employee Director Compensation Policy Under the Company’s non-employee director compensation policy, all non-employee directors will be paid an annual retainer fee of $50,000 and such additional fees as are set forth in the following table. All payments will be made quarterly in arrears. Non-Employee Director Annual Fee Lead Director $ 35,000 Non-Executive Chair $ 30,00
May 7, 2024	EX-99.1	Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA Exhibit 99.1 Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update - First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million - - On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 - - Phase 3 trial evalu
May 7, 2024	EX-10.4	Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan Performance Unit Agreement Exhibit 10.4 RHYTHM PHARMACEUTICALS, INC. 2017 EQUITY INCENTIVE PLAN Performance Unit Agreement This Performance Unit Agreement (this “Agreement”), dated as of [ ● ] (the “Date of Grant”), is between Rhythm Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) and [ ● ] (the “Participant”). Capitalized terms used in this Agreement without definition
April 30, 2024	SC 13D/A	RYTM / Rhythm Pharmaceuticals, Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - NEW ENTERPRISE ASSOCIATES 13, LP (RHYTHM PHARMACEUTICALS) - SCHEDULE 13D/A(#2E) Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 76243J105 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 26, 2024	ARS	ARS This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is subject to the “safe harbor” created by those sections.
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
April 17, 2024	SC 13D/A	RYTM / Rhythm Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d803502dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76243J105 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10
April 17, 2024	EX-99.5	JOINT FILING AGREEMENT EX-99.5 Exhibit 5 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: April 17, 2024 PERCE
April 16, 2024	EX-3.1	Certificate of Designations Exhibit 3.1 Rhythm Pharmaceuticals, Inc. Certificate of Designations Series A Convertible Preferred Stock April 15, 2024 Table of Contents Page    Section 1. Definitions 1 Section 2. Rules of Construction 13 Section 3. The Convertible Preferred Stock 14 (a) Designation; Par Value 14 (b) Number of Authorized Shares 14 (c) Form, Dating and Denominations 14 (d) Method of Payment; Delay When Payment D
April 16, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
April 3, 2024	SC 13D/A	RYTM / Rhythm Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d815846dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76243J105 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10
April 1, 2024	EX-99.1	Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing -- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 -- Exhibit 99.1 Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing - Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 - BOSTON, April 1, 2024 – Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neur
April 1, 2024	EX-10.1	Investment Agreement dated April 1, 2024, by and between Rhythm Pharmaceuticals, Inc., certain affiliates of Perceptive Advisors LLC, and certain other investors Exhibit 10.1 INVESTMENT AGREEMENT dated as of April 1, 2024 by and among Rhythm Pharmaceuticals, Inc. and the Purchasers party hereto. TABLE OF CONTENTS Page Article I PURCHASE; CLOSING 1 1.1 Purchase; Use of Proceeds 1 1.2 Closing 1 1.3 Closing Conditions 2 Article II  REPRESENTATIONS AND WARRANTIES 5 2.1 Representations and Warranties of the Company 5 2.2 Representations and Warranties of the Pu
April 1, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
March 20, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d813811dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.
March 20, 2024	SC 13D	RYTM / Rhythm Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D Activist Investment SC 13D 1 d813811dsc13d.htm SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76243J105 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 20
February 29, 2024	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Rhythm Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Rhythm Pharmaceuticals, Inc.
February 29, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
February 29, 2024	424B5	Up to $200,000,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270233 PROSPECTUS SUPPLEMENT (To Prospectus dated March 2, 2023) Up to $200,000,000 Common Stock We previously entered into a Sales Agreement, dated November 2, 2021, or the Sales Agreement, with Cowen and Company LLC, or TD Cowen, relating to the offer and sale of shares of our common stock, $0.001 par value per share, from
February 29, 2024	EX-10.25	Exclusive License Agreement, dated January 4, 2024, by and between Rhythm Pharmaceuticals, Inc. and LG Chem, Ltd. Exhibit 10.25 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Execution Version EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of January 4, 2024 (the “Effective Da
February 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) RHYTHM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2017 Incentive Award
February 29, 2024	EX-97.1	Policy for Recovery of Erroneously Awarded Compensation Exhibit 97 RHYTHM PHARMACEUTICALS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Rhythm Pharmaceuticals, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subje
February 29, 2024	EX-1.1	Amendment No. 1 to Sales Agreement, dated as of February 29, 2024, between Rhythm Pharmaceuticals, Inc. and Cowen and Company, LLC. Exhibit 1.1 RHYTHM PHARMACEUTICALS, Inc. Common Stock AMENDMENT NO. 1 TO SALES AGREEMENT February 29, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to the Sales Agreement, dated November 2, 2021 (the “Agreement”), by and between Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“Cowen”). T
February 29, 2024	10-K	‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 29, 2024	S-8	As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No.
February 29, 2024	EX-21.1	List of Subsidiaries. Exhibit 21.1 Subsidiaries of Rhythm Pharmaceuticals, Inc. Entity Jurisdiction of Organization or Incorporation Rhythm Pharmaceuticals Limited Ireland Rhythm Securities Corp. Massachusetts Rhythm Pharmaceuticals Netherlands, B.V. The Netherlands Rhythm Pharmaceuticals UK Limited Rhythm Pharmaceuticals France SAS Rhythm Pharmaceuticals Italy S.r.L. Rhythm Pharmaceuticals Canada Inc. United Kingdom F
February 29, 2024	EX-10.6	Summary of Non-Employee Director Compensation Policy Exhibit 10.6 Summary of Non-Employee Director Compensation Policy Under the Company’s non-employee director compensation policy, all non-employee directors will be paid an annual retainer fee of $50,000 and such additional fees as are set forth in the following table. All payments will be made quarterly in arrears. Non-Employee Director Annual Fee Lead Director $ 35,000 Non-Executive Chair $ 30,00
February 22, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
February 22, 2024	EX-99.1	Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update -- Fourth quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of P Exhibit 99.1 Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update - Fourth quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $24.2 million - - Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top-line data on track for 1H2025 - - Announced Phase 3 development plans for setmelanot
February 14, 2024	EX-99.1	Exhibit 1: Joint Filing Agreement EX-99.1 2 tm246065d16ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio
February 14, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d1613ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem
February 14, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SC 13G/A 1 tm242424d24sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 6)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the a
February 13, 2024	SC 13G	RYTM / Rhythm Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01825-rhythmpharmaceutical.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Rhythm Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 76243J105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule p
February 12, 2024	EX-99.1	AGREEMENT EX-99.1 2 d758102dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 12, 2
February 12, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 rytma621224.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) COM (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat
February 12, 2024	SC 13G	RYTM / Rhythm Pharmaceuticals, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d758102dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76243J105 (CUSIP Number) February 1, 2024 (Date of Event Which Requires Filing of this Statement) Chec
February 5, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / GOLDMAN SACHS GROUP INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* RHYTHM PHARMACEUTICALS, INC. - (Name of Issuer) Common Stock, $0.001 par value per share - (Title of Class of Securities) 76243J105 - (CUSIP Number) December 29, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to
January 24, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment us76243j1051012324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) RHYTHM PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 76243J105 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur
January 23, 2024	SC 13G/A	RYTM / Rhythm Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 RhythmPharInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING RHYTHM PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 76243J105 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURS
January 4, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commi
January 4, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commi
December 18, 2023	EX-3.1	Amended and Restated Bylaws. Exhibit 3.1 RHYTHM PHARMACEUTICALS, INC. AMENDED AND RESTATED BYLAWS Article I. — General. 1.1.          Offices. The registered office of Rhythm Pharmaceuticals, Inc. (the “Company”) shall be in the City of Wilmington, County of New Castle, State of Delaware. The Company may also have offices at such other places both within and without the State of Delaware as the board of directors of the Compa
December 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 RHYTHM PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Com
December 6, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223
November 7, 2023	EX-99.1	Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update -- Third quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $22.5 million -- -- More than 100 international patients on reimbursed IMCIVRE Exhibit 99.1 Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update - Third quarter 2023 net revenue from global sales of IMCIVREE® (setmelanotide) of $22.5 million - - More than 100 international patients on reimbursed IMCIVREE therapy - - Phase 3 hypothalamic obesity trial on track to be fully enrolled by the end of 2023 - - 25.5% mean BMI reduction achieved at o
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
September 7, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc. / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5*) RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76243J105 (CUSIP Number) August 31, 2023 (Date of Event Which Requires Filing of
August 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 RHYTHM PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commi
August 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 RHYTHM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
August 3, 2023	EX-10.1	Amended & Restated Offer Letter, dated July 28, 2023, by and between the Registrant and Daivd P. Meeker. Exhibit 10.1 July 28, 2023 David P. Meeker, M.D. Dear David: On behalf of Rhythm Pharmaceuticals, Inc. (the “Company”), I am pleased to set forth below the updated terms of your employment with the Company. You and the Company previously were parties to the employment offer letter, dated July 16, 2020 (the “Prior Letter”). This letter agreement amends and supersedes the Prior Letter in its entiret
August 3, 2023	EX-10.4	Amended & Restated Offer Letter, dated August 3, 2023, by and between the Registrant and Hunter Smith. Exhibit 10.4 August 3, 2023 Hunter Smith Dear Hunter: On behalf of Rhythm Pharmaceuticals, Inc. (the “Company”), I am pleased to set forth below the updated terms of your employment with the Company. You and the Company previously were parties to the second amended and restated employment offer letter, dated December 21, 2017 (the “Prior Letter”). This letter agreement amends and supersedes the Pr
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 RHYTHM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
August 3, 2023	EX-10.2	Amended & Restated Offer Letter, dated July 28, 2023, by and between the Registrant and Joseph Shulman. Exhibit 10.2 July 28, 2023 Joe Shulman Dear Joe, On behalf of Rhythm Pharmaceuticals, Inc. (the “Company”), I am pleased to set forth below the updated terms of your employment with the Company. You and the Company previously were parties to the employment offer letter, dated June 23, 2020 (the “Prior Letter”). This letter agreement amends and supersedes the Prior Letter in its entirety. Employmen
August 3, 2023	EX-10.3	Amended & Restated Offer Letter, dated August 3, 2023, by and between the Registrant and Jennifer Chien. Exhibit 10.3 August 3, 2023 Jennifer Chien Dear Jennifer, On behalf of Rhythm Pharmaceuticals, Inc. (the “Company”), I am pleased to set forth below the updated terms of your employment with the Company. You and the Company previously were parties to the employment offer letter, dated September 25, 2020 (the “Prior Letter”). This letter agreement amends and supersedes the Prior Letter in its entir
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
August 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHYT
August 1, 2023	EX-99.1	Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business -- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE® (setmelanotide) -- -- Strong U.S. commercial progress continues with more than 125 ne Exhibit 99.1 Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update - Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE® (setmelanotide) - - Strong U.S. commercial progress continues with more than 125 new prescriptions for Bardet- Biedl syndrome (BBS) in 2Q 2023, more than 425 since FDA approval - - Achieved commercial sales milestone
July 7, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc. / BlackRock Inc. Passive Investment us76243j1051070723.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) RHYTHM PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 76243J105 - (CUSIP Number) June 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
June 22, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
May 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 RHYTHM PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissio
May 2, 2023	EX-99.1	Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update -- Strong U.S. commercial progress continues for IMCIVREE® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received since FDA Exhibit 99.1 Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update - Strong U.S. commercial progress continues for IMCIVREE® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received since FDA approval - - Launched IMCIVREE for BBS in Germany with federal reimbursement - - First patients dosed in pivotal Phase 3 trial evaluating
May 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38223 RHY
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru
April 27, 2023	ARS	ARS Cautionary Note Regarding Forward-Looking Statements This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is subject to the “safe harbor” created by those sections.
March 29, 2023	SC 13D/A	RYTM / Rhythm Pharmaceuticals Inc. / NEW ENTERPRISE ASSOCIATES 13 LP - NEW ENTERPRISE ASSOCIATES 13, LP (RHYTHM PHARMACEUTICALS) - SCHEDULE 13D/A(#1) Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 76243J105 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 8
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 RHYTHM PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
March 2, 2023	S-3ASR	As filed with the Securities and Exchange Commission on March 2, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 2, 2023 Registration No.
March 2, 2023	EX-4.3	Form of Indenture. Exhibit 4.3 RHYTHM PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Esta
March 2, 2023	S-8	As filed with the Securities and Exchange Commission on March 2, 2023 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No.
March 2, 2023	EX-1.2	Sales Agreement, dated as of November 2, 2021, by and between Rhythm Pharmaceuticals, Inc. and Cowen & Company, LLC. Exhibit 1.2 RHYTHM PHARMACEUTICALS, INC. $100,000,000 Common Stock SALES AGREEMENT November 2, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Rhythm Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees t
March 2, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Rhythm Pharmaceuticals, Inc.
March 2, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) RHYTHM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered1 Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2017 Incentive Award P
March 1, 2023	EX-4.3	Description of the Registrant’s Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934. Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Rhythm Pharmaceuticals, Inc. (“we,” “our,” “us,” or the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, par value $0.001 per share. The following description of o
March 1, 2023	10-K	‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 RHYTHM PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
March 1, 2023	EX-10.6	Summary of Non-Employee Director Compensation Policy Exhibit 10.6 Summary of Non-Employee Director Compensation Policy Under the Company’s non-employee director compensation policy, all non-employee directors will be paid an annual retainer fee of $50,000 and such additional fees as are set forth in the following table. All payments will be made quarterly in arrears. Non-Employee Director Annual Fee Lead Director $ 35,000 Non-Executive Chair $ 30,00
March 1, 2023	EX-21.1	List of Subsidiaries. Exhibit 21.1 Subsidiaries of Rhythm Pharmaceuticals, Inc. Entity Jurisdiction of Organization or Incorporation Rhythm Pharmaceuticals Limited Ireland Rhythm Securities Corp. Massachusetts Rhythm Pharmaceuticals Netherlands, B.V. The Netherlands Rhythm Pharmaceuticals UK Limited Rhythm Pharmaceuticals France SAS Rhythm Pharmaceuticals Italy S.r.L. Rhythm Pharmaceuticals Canada Inc. United Kingdom F
March 1, 2023	EX-99.1	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results -- IMCIVREE® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- -- IMCIVREE now ava Exhibit 99.1 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results - IMCIVREE® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval - - IMCIVREE now available in eight ex-U.S. markets; first commercial sales for BBS expected in Germany in 2Q 2023 - - Pivotal Phase 3 trial evaluating setmelan
March 1, 2023	EX-10.20	Offer Letter, dated June 23, 2020, by and between the Registrant and Joseph Shulman. Exhibit 10.20 June 23, 2020 Joe Shulman 116 Auburn Street Newton, MA 02466 Dear Joe Congratulations on your offer of employment with Rhythm Pharmaceuticals (also referred to in this letter as the “Company”). I am confident you will find your career with Rhythm to be filled with opportunities, challenges and rewards. We take great pride in hiring professionals who have talent, drive, creativity and
March 1, 2023	EX-2.2	Share Purchase Agreement, by and between Rhythm Pharmaceuticals Netherlands B.V. and Xinvento B.V., dated February 27, 2023. Exhibit 2.2 Execution Version SHARE PURCHASE AGREEMENT BY AND AMONG RHYTHM PHARMACEUTICALS NETHERLANDS B.V., THE SELLERS LISTED ON THE SIGNATURE PAGE HERETO, XINVENTO B.V. AND THE SELLER REPRESENTATIVE IDENTIFIED HEREIN DATED AS OF FEBRUARY 24, 2023 CONTENTS Page Section 1. DEFINITIONS AND INTERPRETATIONS 1 1.1 Certain Definitions 1 1.2 Interpretation 14 Section 2. PURCHASE AND SALE 15 2.1 Sale an
February 14, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d38sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat
February 9, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / JANUS HENDERSON GROUP PLC - JHG PLC OWNS <5% Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 5* Name of Issuer: RHYTHM PHARMACEUTICALS, INC. Title of Class of Securities: Common Stock CUSIP Number: 76243J105 Date of Event Which Requires Filing of this Statement: 12/31/2022 Check the appropriate box to designate the rule pursuant to which this Schedu
February 9, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment SC 13G/A 1 rytma520923.htm PRIMECAP MANAGEMENT CO/CA/ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) COM (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriat
February 8, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / GOLDMAN SACHS GROUP INC Passive Investment SC 13G/A 1 RHYTHM.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* RHYTHM PHARMACEUTICALS, INC. - (Name of Issuer) Common Stock, par value $0.001 per share - (Title of Class of Securities) 76243J105 - (CUSIP Number) December 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check t
February 3, 2023	SC 13G	RYTM / Rhythm Pharmaceuticals Inc / BlackRock Inc. Passive Investment us76243j1051020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) RHYTHM PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 76243J105 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs
February 3, 2023	SC 13G	RYTM / Rhythm Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING RHYTHM PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 76243J105 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDUL
February 1, 2023	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 RHYTHM PHARMACEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commi
January 9, 2023	EX-99.1	© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® January 2023 Rhythm Pharmaceuticals Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases by rapidly advancing care EX-99.1 2 tm232248d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 © Rhythm® Pharmaceuticals, Inc. All rights reserved. ® January 2023 Rhythm Pharmaceuticals Transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R pathway diseases by rapidly advancing care and precision medicines addressing the root cause ® 2 This presentation contains certain for
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 8, 2022	EX-99.1	Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update -- U.S. launch of IMCIVREE® (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions since FDA approval – -- EC au Exhibit 99.1 Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update - U.S. launch of IMCIVREE? (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions since FDA approval ? - EC authorization for IMCIVREE expanded to include BBS; UK launch in POMC and LEPR deficiencies underway ? - Setmelanotide received FDA Breakthro
November 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
November 3, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Comm
October 7, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SCHEDULE 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
September 15, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 14, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation or o
September 15, 2022	EX-1.1	Underwriting Agreement, dated as of September 14, 2022, between Rhythm Pharmaceuticals, Inc. and Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and Wells Fargo Securities, LLC, as representatives of the underwriters named therein. EX-1.1 2 tm2225931d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 EXECUTION VERSION 4,800,000 Shares Rhythm Pharmaceuticals, Inc. Common Stock ($0.001 par value) UNDERWRITING AGREEMENT September 14, 2022 September 14, 2022 Cowen and Company, LLC Stifel, Nicolaus & Company, Incorporated Wells Fargo Securities, LLC c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 c/o Stifel, Nicolaus & C
September 15, 2022	424B5	4,800,000 Shares RHYTHM PHARMACEUTICALS, INC. Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5) ? ?Registration No. 333-260689 ? PROSPECTUS SUPPLEMENT(To Prospectus dated November 15, 2021) ? 4,800,000 Shares RHYTHM PHARMACEUTICALS, INC. Common Stock We are offering 4,800,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?RYTM.? On September 14, 2022, the last reported sale price for our
September 14, 2022	424B5	RHYTHM PHARMACEUTICALS, INC. Common Stock TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed.
August 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 3, 2022	EX-10.1	Revenue Interest Financing Agreement, dated June 16, 2022, by and between the Company and entities managed by HealthCare Royalty Management, LLC [***] Certain information in this document has been omitted pursuant to Regulation S-K, Item (601)(b)(10).
August 2, 2022	EX-99.1	Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update -- Received FDA approval for IMCIVREE® (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome -- -- U.S. launch off to a strong start Exhibit 99.1 Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update - Received FDA approval for IMCIVREE® (setmelanotide) as the first-ever therapy for patients with Bardet-Biedl syndrome - - U.S. launch off to a strong start with more than 50 IMCIVREE prescriptions written for patients with BBS in first six weeks since FDA approval - - EMA’s CHMP recommended expa
August 2, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commis
July 8, 2022	SC 13G	RYTM / Rhythm Pharmaceuticals Inc / BlackRock Inc. Passive Investment us76243j1051070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) RHYTHM PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 76243J105 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
June 16, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
June 10, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissi
May 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 3, 2022	EX-99.1	Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update -- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approva Exhibit 99.1 Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update - Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval - - First commercial patients treated with IMCIVREE® (setmelanotide) in France under paid early access program - - First patients enroll
May 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commissio
April 28, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amend UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 28, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) DEF 14A 1 tm223476-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
April 11, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76243J105 (CUSIP Number) March 31, 2022 (Date of Event Which Requires Filing of t
April 6, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
April 6, 2022	EX-99.1	© Rhythm® Pharmaceuticals, Inc. All rights reserved. ® April 2022 Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity Exhibit 99.1 ? Rhythm? Pharmaceuticals, Inc. All rights reserved. ? April 2022 Rhythm Pharmaceuticals Targeting MC4R pathway and transforming the care of patients with rare genetic diseases of obesity ? 2 This presentation contains certain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including wit
March 1, 2022	S-8	As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.
March 1, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) RHYTHM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2017 Incentive Award
March 1, 2022	EX-10.10	License Agreement, dated December 3, 2021, by and between the Registrant and RareStone Group Ltd. Exhibit 10.10 ? [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. CONFIDENTIAL Execution Copy EXCLUSIVE LICENSE AGREEMENT THIS EXCLUSIVE LICENSE AGREEMENT (this ?Agreement?) effective as of December 3, 2021 (the ?Effec
March 1, 2022	EX-99.1	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results -- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany Exhibit 99.1 Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Preparations continue for U.S. commercial launch in June 2022 in BBS and Alstr?m syndrome, pending FDA approval - - First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 ? - Enrollment completed in Phase 2 trial evaluating setmelanotide in patients with hypothalamic obesity - - I
March 1, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 tm227881d1ex-filingfees.htm EX-FILING FEES Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) RHYTHM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Pr
March 1, 2022	EX-10.6	Summary of Non-Employee Director Compensation Policy Exhibit 10.6 ? Summary of Non-Employee Director Compensation Policy Under the Company?s non-employee director compensation policy, all non-employee directors will be paid an annual retainer fee of $47,500 and such additional fees as are set forth in the following table. All payments will be made quarterly in arrears. Non-Employee Director Annual Fee Lead Director $ 35,000 Non-Executive Chair $ 30,
March 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 RHYTHM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38223 46-2159271 (State or other jurisdiction of incorporation) (Commiss
March 1, 2022	EX-10.21.2	Consulting Agreement, dated September 11, 2021, by and between the Registrant and Murray Stewart, D.M., F.R.C.P. ? Exhibit 10.21.2 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is entered effective as of this 11th day of September, 2021 (the ?Effective Date?) between Rhythm Pharmaceuticals, Inc., a Delaware corporation located at 222 Berkeley Street, Suite 1200, Boston, MA 02116 (the ?Company?), and Murray Stewart, D.M., F.R.C.P. (the ?Consultant?), residing or having a principal place of
March 1, 2022	EX-10.5.2	2022 Employment Inducement Plan Form of Restricted Stock Unit Agreement Exhibit 10.5.2 RHYTHM PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT PLAN Restricted Stock Unit Agreement This Restricted Stock Unit Agreement (this ?Agreement?), dated as of , 20 (the ?Date of Grant?), is between Rhythm Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?) and (the ?Participant?). Capitalized terms used in this Agreement without
March 1, 2022	EX-10.5.1	2022 Employment Inducement Plan and Form of Option Agreement Exhibits 10.5.1 ? ? ? ? ? RHYTHM PHARMACEUTICALS, INC. 2022 EMPLOYMENT INDUCEMENT PLAN ? ? ? Table Of Contents 1.Purpose2 2.Definitions2 3.Term of the Plan5 4.Stock Subject to the Plan5 5.Administration6 6.Authorization of Grants6 7.Specific Terms of Awards7 8.Adjustment Provisions11 9.Change of Control14 10.Settlement of Awards14 11.Reservation of Stock16 12.Limitation of Rights in Stock; No Spec
March 1, 2022	S-8	As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.
March 1, 2022	10-K	‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 1, 2022	EX-21.1	List of Subsidiaries. ? Exhibit 21.1 ? Subsidiaries of Rhythm Pharmaceuticals, Inc. ? Entity Jurisdiction of Organization or Incorporation Rhythm Pharmaceuticals Limited ? Ireland Rhythm Securities Corp. Massachusetts Rhythm Pharmaceuticals Netherlands, B.V. ? The Netherlands Rhythm Pharmaceuticals UK Limited Rhythm Pharmaceuticals France SAS Rhythm Pharmaceuticals Italy S.r.L. Rhythm Pharmaceuticals Canada Inc. ? Unit
February 14, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing o
February 14, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - RHYTHM PHARMACEUTICALS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* RHYTHM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 11, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 10, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / JANUS HENDERSON GROUP PLC - JANUS HENDERSON GROUP PLC OWNS >5% Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 4* Name of Issuer: RHYTHM PHARMACEUTICALS, INC. Title of Class of Securities: Common Stock CUSIP Number: 76243J105 Date of Event Which Requires Filing of this Statement: 12/31/2021 Check the appropriate box to designate the rule pursuant to which this Schedu
February 10, 2022	SC 13G/A	RYTM / Rhythm Pharmaceuticals Inc / PRIMECAP MANAGEMENT CO/CA/ - PRIMECAP MANAGEMENT CO/CA/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Rhythm Pharmaceuticals, Inc. (Name of Issuer) COM (Title of Class of Securities) 76243J105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

RYTM / Rhythm Pharmaceuticals, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings